A proof of principle , randomized study analyzing secondary adjuvant treatment intervention with trastuzumab-deruxtecan in patients with HER2 positive/HER2 low early breast cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Trastuzumab-deruxtecan (Primary) ; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Neratinib
Indications Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms SURVIVE-HERoes

15 Feb 2024 New trial record
09 Dec 2023 Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com